PNC-27 - 10MG

PNC-27 is an experimental anticancer peptide being investigated primarily in laboratory and preclinical research. It is not an established or approved cancer treatment. PNC-27 — Potential Research Benefits Selective targeting of cancer cells: Research suggests PNC-27 may preferentially target certain cancer cells while having substantially less effect on normal cells studied. Cancer-cell membrane disruption: PNC-27 interacts with HDM2/MDM2 proteins expressed on the surface of certain cancer cells and appears to form pores in the cell membrane, potentially causing rapid cell destruction. Unique mechanism of action: Rather than depending primarily on traditional programmed cell death (apoptosis), PNC-27 appears capable of causing membrane lysis and necrotic cell death. Potential activity despite abnormal p53: Because its proposed mechanism involves membrane-associated HDM2, PNC-27 has shown experimental activity in some cancer models where normal p53 function is absent or impaired. Investigated in leukemia: Preclinical research has examined PNC-27 against acute myeloid leukemia (AML) cells, including leukemia-stem-cell-enriched populations. Potential broad research applications: Since HDM2 can be present on the membranes of different cancer-cell types, researchers have investigated whether PNC-27 could have activity across multiple cancers.